Shanghai Yidi Biotechnology Co. Ltd. has identified dihydrothienopyrimidine compounds acting as phosphodiesterase PDE4B2 and/or phosphodiesterase PDE4D2 inhibitors reported to be useful for the treatment of autoimmune disorders, metabolic diseases, neurological diseases and inflammatory disorders.

Immunophage Biomedical Co. Ltd. has divulged G-protein coupled receptor 183 (GPR183; EBI2) antagonists reported to be useful for the treatment of autoimmune disease, cancer, liver diseases, osteoporosis and neuropathic pain.

Shanghai Huilun Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety through a linker reported to be useful for the treatment of cancer, neurodegeneration, infections, autoimmune disorders, metabolic diseases, cardiovascular disorders, genetic diseases and inflammatory disorders, among others.

Pfizer Inc. has disclosed drugs targeting GTPase KRAS and its mutant forms reported to be useful for the treatment of cancer.

Dartmouth College has divulged fatty acid mimetics acting as free fatty acid FFA1 receptor (GPR40) and/or FFA4 receptor (GPR120) agonists reported to be useful for the treatment of obesity and type 2 diabetes.

Scientists at Centre Hospitalier Regional Universitaire de Lille, Centre National de la Recherche Scientifique, Institut National De La Santé et de la Recherche Médicale, Institut Pasteur de Lille and Université de Lille have patented conjugates comprising siderophore moieties covalently linked to cargo moieties through a linker reported to be useful for the diagnosis and treatment of bacterial infections.

Biocells (Beijing) Biotech Co. Ltd. has identified aquaporin-4 (AQP4) inhibitors reported to be useful for the treatment of cerebral ischemia.

National Institutes of Pharmaceutical R&D Co. Ltd. has synthesized fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.

Baobab Aibio Co. Ltd. has disclosed transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.

Bivision Biomedical Technology (Nanjing) Co. Ltd. has described radiolabeled-metal complexes targeting fibroblast activation protein α (FAP) reported to be useful for the diagnosis and treatment of cancer.